A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma.
BRF2
Cancer
Prognostic marker
RNA polymerase III
TFIIIB
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
11 Nov 2020
11 Nov 2020
Historique:
received:
05
08
2020
accepted:
26
10
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
11
5
2021
Statut:
epublish
Résumé
Deregulation of the RNA polymerase III specific TFIIIB subunit BRF2 occurs in subtypes of human cancers. However, correlations between BRF2 alterations and clinical outcomes in breast cancer are limited. We conducted this review to analyze BRF2 alterations in genomic data sets housed in Oncomine and cBioPortal to identify potential correlations between BRF2 alterations and clinical outcomes. The authors queried both Oncomine and cBioPortal for alterations in BRF2 in human cancers and performed meta-analyses identifying significant correlations between BRF2 and clinical outcomes in invasive breast cancer (IBC). A meta cancer outlier profile analysis (COPA) of 715 data sets (86,733 samples) in Oncomine identified BRF2 as overexpressed in 60% of breast cancer data sets. COPA scores in IBC data sets (3594 patients) are comparable for HER2 (24.211, median gene rank 60) and BRF2 (29.656, median gene rank 36.5). Overall survival in IBC patients with BRF2 alterations (21%) is significantly decreased (p = 9.332e-3). IBC patients with BRF2 alterations aged 46 to 50 have a significantly poor survival outcome (p = 7.093e-3). Strikingly, in metastatic breast cancer, BRF2 is altered in 33% of women aged 45-50. BRF2 deletions are predominant in this age group. This study suggests BRF2 may be an prognostic biomarker in invasive breast carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
Deregulation of the RNA polymerase III specific TFIIIB subunit BRF2 occurs in subtypes of human cancers. However, correlations between BRF2 alterations and clinical outcomes in breast cancer are limited. We conducted this review to analyze BRF2 alterations in genomic data sets housed in Oncomine and cBioPortal to identify potential correlations between BRF2 alterations and clinical outcomes.
METHODS
METHODS
The authors queried both Oncomine and cBioPortal for alterations in BRF2 in human cancers and performed meta-analyses identifying significant correlations between BRF2 and clinical outcomes in invasive breast cancer (IBC).
RESULTS
RESULTS
A meta cancer outlier profile analysis (COPA) of 715 data sets (86,733 samples) in Oncomine identified BRF2 as overexpressed in 60% of breast cancer data sets. COPA scores in IBC data sets (3594 patients) are comparable for HER2 (24.211, median gene rank 60) and BRF2 (29.656, median gene rank 36.5). Overall survival in IBC patients with BRF2 alterations (21%) is significantly decreased (p = 9.332e-3). IBC patients with BRF2 alterations aged 46 to 50 have a significantly poor survival outcome (p = 7.093e-3). Strikingly, in metastatic breast cancer, BRF2 is altered in 33% of women aged 45-50. BRF2 deletions are predominant in this age group.
CONCLUSION
CONCLUSIONS
This study suggests BRF2 may be an prognostic biomarker in invasive breast carcinoma.
Identifiants
pubmed: 33176745
doi: 10.1186/s12885-020-07569-8
pii: 10.1186/s12885-020-07569-8
pmc: PMC7659115
doi:
Substances chimiques
BRF2 protein, human
0
Biomarkers, Tumor
0
Transcription Factor TFIIIB
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1093Références
Nature. 2003 Jan 16;421(6920):290-4
pubmed: 12529648
PLoS One. 2014 Feb 11;9(2):e88032
pubmed: 24523874
PLoS Med. 2016 Dec 27;13(12):e1002201
pubmed: 28027327
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Endocr Relat Cancer. 2010 Sep 23;17(4):R245-62
pubmed: 20647302
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncogene. 2005 Aug 4;24(33):5235-45
pubmed: 15897872
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
Ann Oncol. 2001;12 Suppl 1:S23-8
pubmed: 11521717
Genes Dev. 2000 Oct 15;14(20):2650-63
pubmed: 11040218
Biomolecules. 2017 Jul 11;7(3):
pubmed: 28696357
Clin Med Insights Pathol. 2015 Dec 21;8:23-31
pubmed: 26740749
Online J Biol Sci. 2010 Sep 30;10(3):114-125
pubmed: 21479160
Mol Cancer. 2011 Apr 25;10:47
pubmed: 21518452
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
J Clin Oncol. 2009 Oct 1;27(28):4701-8
pubmed: 19720911
Cold Spring Harb Perspect Med. 2014 May 01;4(5):
pubmed: 24789877
Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
pubmed: 20586616
EMBO J. 1998 Jun 1;17(11):3112-23
pubmed: 9606193
Cancer Res. 2004 Jan 1;64(1):40-7
pubmed: 14729606
Nucleic Acids Res. 2019 Jan 8;47(D1):D948-D954
pubmed: 30247620
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14200-5
pubmed: 11121026
Med Oncol. 2013 Jun;30(2):553
pubmed: 23550276
Br J Cancer. 2000 Dec;83(12):1688-95
pubmed: 11104567
Oncogene. 2004 Apr 19;23(18):3208-16
pubmed: 15094770
Cell Cycle. 2004 Sep;3(9):1133-7
pubmed: 15467447
Toxicol Sci. 2010 May;115(1):66-79
pubmed: 20106945
Invasion Metastasis. 1994-1995;14(1-6):329-36
pubmed: 7657526
Biochem Biophys Res Commun. 2007 Sep 7;360(4):778-83
pubmed: 17624304
BMC Mol Biol. 2008 Aug 12;9:74
pubmed: 18700021
Cell Cycle. 2003 May-Jun;2(3):181-4
pubmed: 12734418
Biomed Res Int. 2014;2014:530786
pubmed: 24738062
Genes Dev. 2002 Oct 15;16(20):2593-620
pubmed: 12381659
Oncogene. 2017 Dec 7;36(49):6793-6804
pubmed: 28846112
J Mol Biol. 2009 Apr 3;387(3):523-31
pubmed: 19361418
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9580-E9589
pubmed: 30257941
Mol Cell Biol. 1999 Jun;19(6):4255-61
pubmed: 10330166
BMC Cancer. 2015 Nov 16;15:905
pubmed: 26573593
Sign Transduct Insights. 2016 Feb 10;5:1-7
pubmed: 26989346
Surg Today. 2019 Feb;49(2):158-169
pubmed: 30182305
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Microbiology (Reading). 2013 Dec;159(Pt 12):2501-2512
pubmed: 24025606
Clin Cancer Res. 2011 Apr 1;17(7):1850-7
pubmed: 21447720
Breast Cancer Res Treat. 2019 Apr;174(3):795-805
pubmed: 30659433
Transl Oncol. 2017 Oct;10(5):818-827
pubmed: 28846937
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Toxicol Sci. 2002 Oct;69(2):354-61
pubmed: 12377984
ESMO Open. 2018 Nov 1;3(7):e000452
pubmed: 30425850
PLoS Med. 2010 Jul 27;7(7):e1000315
pubmed: 20668658
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Genome Med. 2015 Oct 27;7:112
pubmed: 26507825
Genes Dev. 1991 Feb;5(2):232-43
pubmed: 1995415
Nat Struct Mol Biol. 2019 Nov;26(11):1035-1043
pubmed: 31686052
Cancer Biol Ther. 2015;16(7):1080-7
pubmed: 25961141
Mol Cell Biol. 2005 Nov;25(21):9406-18
pubmed: 16227591
BMC Mol Biol. 2010 Mar 12;11:21
pubmed: 20226026
Mol Cell Biol. 2008 Jun;28(12):4204-14
pubmed: 18391023
Breast Cancer Res Treat. 2010 Jul;122(1):45-53
pubmed: 19701705
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Mol Cell Biol. 2002 Jun;22(12):3959-69
pubmed: 12024010